Results 201 to 210 of about 272,841 (277)

neuer PDA

netbib, 2004
openaire   +2 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Patent Ductus Arteriosus in Preterm Neonates: A 2025 Synthesis of Evidence-Based Paradigms and Emerging Clinical Strategies. [PDF]

Pediatr Discov
Bhatt AH, Nimbalkar SM, Patel DV, Pujara RK.   +3 more
europepmc   +1 more source

Polydopamine‐Mediated Grafting of Cationic Polymer Brushes for Adsorption of Fluorinated Compounds

Chemistry – A European Journal, EarlyView.
We introduce a versatile approach to fabricate tunable charged interfaces by functionalizing stonewool fibers with a polydopamine (PDA)–quaternary amine coating via a grafting‐to method. The modified surfaces exhibit rapid, concentration‐dependent adsorption of anionic species driven by electrostatic interactions.
Agnes C. Morrissey, Federica Sbordone, Fred Pashley‐Johnson, Aaron S. Micallef, Bart van de Worp, Neomy Zaquen, Prasanna Egodawatta, Laura Delafresnaye, Lukas Michalek, Christopher Barner‐Kowollik   +9 more
wiley   +1 more source

The incremental value of invasive coronary angiographic characteristics in predicting the success of retrograde chronic total occlusion percutaneous coronary intervention via invisible collateral channels. [PDF]

Quant Imaging Med Surg
Jia Q, Hu T, Dong Y, Huang Y, Huang M, Zhang B.   +5 more
europepmc   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

Clinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen, Jeffrey L. Woodhead, Brett A. Howell, Lisl K. M. Shoda, Dolly A. Parasrampuria, Jiayin Huang, Megumi Iwai, Faith D. Ottery, Xuegong Wang, Marci English, Kentaro Miyazaki, Paul B. Watkins   +11 more
wiley   +1 more source

M2 macrophage-derived extracellular vesicle/polydopamine hydrogel attenuates diabetic periodontitis-induced bone loss via the NEK7/NLRP3/IL-1β pathway. [PDF]

Sci Rep
Cheng Y, Zhao P, Zhang N, Guo J, Niu J, Li F.   +5 more
europepmc   +1 more source

Identification and Structural Elucidation of a New Synthetic Cannabinoid, MDMB‐5′Br‐PINACA, in Seized Herbal Materials

Drug Testing and Analysis, EarlyView.
MDMB‐5Br‐PINACA, a novel synthetic cannabinoid, was identified and structurally characterized in seized herbal products using GC‐MS, LC‐HRMS, and NMR. The discovery underscores ongoing diversification of SCs and the need for vigilant surveillance.
Alexandre Barcia de Godoi, Lucas André Zeoly, Rafael Lanaro, Ingrid Simões Oliveira, Mariana Cepollaro Diana, Mauricio Yonamine, Jose Luiz Costa   +6 more
wiley   +1 more source

Rapid photocontrollable dopamine polymerization for instant adaptive wet adhesion. [PDF]

Nat Commun
Lu Z, Bai S, Lu H, Zhu Z, Yu J, Wang Q, Zhang P, Qian L, Zheng Z, Yu Y.   +9 more
europepmc   +1 more source